The news of Ladenburg Thalmann maintaining a Buy rating on Alterity Therapeutics is positive for the stock. However, the lowering of the price target from $20 to $10 may create uncertainty among investors, potentially offsetting the positive sentiment. Therefore, the short-term impact on the stock price is neutral.